



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q75926

Ryuichi MORISHITA, et al.

Appln. No.: 10/615,262

Group Art Unit: 1633

Confirmation No.: 5695

Examiner: Robert M. Kelly

Filed: July 9, 2003

For: MEDICAMENT COMPRISING HGF GENE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

05/24/2006 SZEWDIE1 00000117 10615262

The present Information Disclosure Statement is being filed (Without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/615,262

Attorney Docket No.: Q75926

Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore a check for the fee of \$180.00 under 37 C.F.R. § 1.17(p) is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Susan J. Mack
Registration No. 30,951

Date: May 23, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/615,262
Confirmation Number	5695
Filing Date	July 9, 2003
First Named Inventor	Ryuichi MORISHITA
Art Unit	1633
Examiner Name	Robert M. Kelly
Attorney Docket Number	Q75926

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,498,144	B1	12-24-2002	Goldberg, et al.
		US 6,989,374	B1	01-24-2006	Morishita, et al.
		US 6,248,722	B1	06-19-2001	Morishita, et al.
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Manuel GONÇALVES, <i>et al.</i> , A concise peer into the background, initial thoughts and practices of human gene therapy, BioEssays, Wiley Periodicals, Inc., 2005, pp. 506-517, Vol. 27, USA.	
		Nicholas MILLER, <i>et al.</i> , Targeted vectors for gene therapy, The FASEB Journal, February 1995, pp. 190-199, Vol. 9, UK	
		Yoshiaki TANIYAMA, <i>et al.</i> , Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model, Molecular Mechanisms of Delayed Angiogenesis in Diabetes, Circulation, The American Heart Association, Inc., November 2001, pp. 2344-2350, Vol. 104, Japan	
		Rohit KHURANA, <i>et al.</i> , Gene Therapy for Cardiovascular Disease A Case for Cautious Optimism, Hypertension, The American Heart Association, Inc., November 2001, pp. 1210-1216, Vol. 38, UK	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.